ReviewFrontiers in immunology2018
Tolerating the Unwelcome Guest; How the Host Withstands Persistent
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Immunotherapy for Melanoma in Patients with Altered Immune Systems: Unique Challenges and Clinical Considerations.Advances in therapy · 2026Review
- A co-evolutionary perspective on humans andeLife · 2026Review
- CpsA mediates infection of recruited lung myeloid cells by Mycobacterium tuberculosis.Cell reports · 2024Article
- Amphibian infection tolerance to chytridiomycosis.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023Review
- High Lethality ofInfection and immunity · 2023Article
- Rapid lethality of mice lacking the phagocyte oxidase and Caspase1/11 followingbioRxiv : the preprint server for biology · 2023Article
- Article
- Understanding the tuberculosis granuloma: the matrix revolutions.Trends in molecular medicine · 2022Review
- Immunological hyporesponsiveness in tuberculosis: The role of mycobacterial glycolipids.Frontiers in immunology · 2022Review
- Mycobacterium tuberculosis Rv2626c-derived peptide as a therapeutic agent for sepsis.EMBO molecular medicine · 2020Article
- Fighting Persistence: How Chronic Infections with Mycobacterium tuberculosis Evade T Cell-Mediated Clearance and New Strategies To Defeat Them.Infection and immunity · 2020Review
- Cavitary tuberculosis: the gateway of disease transmission.The Lancet. Infectious diseases · 2020Review
- Article
- Reconsidering the Optimal Immune Response toAmerican journal of respiratory and critical care medicine · 2020Article
- Article
- Host Cell Targets of Released Lipid and Secreted Protein Effectors ofFrontiers in cellular and infection microbiology · 2020Review
- Mycobacterial Evolution Intersects With Host Tolerance.Frontiers in immunology · 2019Review
- Beyond KillingFrontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Our understanding of the host response to infections has historically focused on "resistance" mechanisms that directly control pathogen replication. However, both pathogen effectors and antimicrobial immune pathways have the capacity to damage host tissue, and the ability to tolerate these insults can also be critical for host survival. These "tolerance" mechanisms may be equally as important as resistance to prevent disease in the context of a persistent infection, such as tuberculosis, when resistance mechanisms are ineffective and the pathogen persists in the tissue for long periods. Host tolerance encompasses a wide range of strategies, many of which involve regulation of the inflammatory response. Here we will examine general strategies used by macrophages and T cells to promote tolerance in the context of tuberculosis, and focus on pathways, such as regulation of inflammasome activation, that are emerging as common mediators of tolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.